Pillars of growth


Heavy bet for R&D
as a future
growth engine

conocer +


Heavy bet on R&D
as a future
growth engine

find out more

Biosimilar de Enoxaparina


A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.

find out more


Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures


2016 net profit


2016 Bemiparin sales in Spain

55 countries

International presence with 22 international partners

4 plants

for manufacturing own and third-party products in Spain

17,5 Mn€

of investment in R&D in 2016 Commitment to innovation

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors


Last news on Rovi 

(See all items)



ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies



9M 2017 Results Press Release

Download our press release published on 8 November to find out the financial results for the first nine months of 2017.

Last annual report


Annual Report 2016

Last regular
public information


Selected financial data